Thymosin Alpha-1

Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B

This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1 (PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed from Hansoh Pharmaceutical of China, in combination with adefovir in HBeAg-positive patients with chronic hepatitis B.

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

A randomized controlled trial to evaluate efficacy and safety of Thymosin-α1 administration in patients with HBV-related Acute-on-chronic liver failure.

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

The purpose of this study is to determine the optimal treatment duration of antiviral therapy for chronic hepatitis B.

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

The investigators postulated that the exploitation of the pro-immunogenic effects of radiotherapy with thymosin might result in abscopal responses among patients with metastatic cancer. The research is designed to evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy combined with thymosin alpha 1. An exploratory biomarker analysis in blood and tumor samples is

Abscopal Effect for Metastatic Colorectal Cancer

Patients with colorectal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response outside the radiation field (abscopal effect) after chemoradiotherapy of a metastatic site in metastatic colorectal cancer patients. 2. To induce the efficacy (effectiveness) of a ne

A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer

This study will enroll patients with limited-stage small cell lung cancer (SCLC). Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1, with a total cycles of 4. Thoracic radiotherapy was performed no later than the three cycle of chemotherapy. Prophylactic cranial irradiation was recommended for pa

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

The purpose of this study is to evaluate the safety and efficacy of Zadaxin® in the treatment of HIV-positive patients with immune reconstitution disorders. Researchers previously used Zadaxin® (Thymosin α-1, Tα1) as an immune adjuvant for people infected with HIV-1 and found that Tα1 and Interferon-α (IFN-α) have a synergistic effect in immune enhancement. In addition, studies have found that the

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

Osteoporotic pain is the most common clinical symptom in elderly patients. The course of pain is prolonged and the effect of clinical treatment is limited. This study will observe the therapeutic effect of thymosin alpha 1 on elderly patient with osteoporotic pain and explore its immunotherapy mechanism.

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

Six hundreds patients with chronic hepatitis B clinically diagnosed as compensated liver cirrhosis are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2 years; the other is entecavir alone for the first 0.5 year, entecavir plus thymosin-α for 1 year, entecavir for another additional 0.5 year.Patients will be assessed at baseline, at every six months for blood cell count, liver fun

The Efficacy and Safety of Thymosin α1 for Sepsis (TESTS): A Multicentre, Double-blind, Randomised, Placebo-Controlled Phase 3 Trial

TESTS was a multicentre, double-blind, randomised, placebo-controlled Phase 3 trial evaluating thymosin α1 in adults aged 18–85 with sepsis. 1,106 participants were randomised (552 thymosin α1; 554 placebo). The primary endpoint was 28-day all-cause mortality. Results published in BMJ in January 2025 showed no significant difference in 28-day mortality between groups (thymosin α1: 17.4% vs placebo: 16.2%; OR 1.09, 95% CI 0.79–1.50; p=0.596). There was no significant benefit in secondary endpoints including 90-day mortality or organ failure scores. The trial did not support routine use of thymosin α1 for sepsis.

Thymosin Alpha-1 for Immune-Related Adverse Events (irAE) Secondary to Immune Checkpoint Inhibitors

This Phase 2 trial evaluates the safety and efficacy of thymosin alpha-1 in managing immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors (ICIs). irAEs represent a major dose-limiting toxicity of PD-1/PD-L1/CTLA-4 blockade therapy. The trial tests whether thymosin alpha-1's immunomodulatory properties — promoting regulatory T cell function and modulating excessive inflammatory responses — can reduce the severity of irAEs while preserving anti-tumour immunity.